Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Chicago, Illinois

Phase 1 cancer trials in Chicago, IL

102 Phase 1 cancer studies are recruiting participants at sites in Chicago as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Chicago at a glance

  • 102 studies are recruiting at a site in Chicago.
  • By phase: Early Phase 1 (5), Phase 1 (50), Phase 1/2 (47).
  • By sponsor: industry (72), university, hospital or other (24), government (6).
  • By research area: Lymphoma (34), Breast Cancer (28), Lung Cancer (22), Prostate Cancer (7), Pancreatic Cancer (6), Melanoma (5).
  • Most recent update to one of these records: November 17, 2026.

Breast cancer studies recruiting in Chicago

Basic details from each study's public record (the 30 most recently updated of 102). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

    • Phase 1
    • Ages 18 and older
    • Female participants
    Sponsor
    Totus Medicines
    Study site
    Northwestern Memorial Hospital
    Registry record
    NCT05683418 · updated
  2. A Phase 1/2 Study of IAM1363 in HER2 Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study site
    University of Chicago
    Registry record
    NCT06253871 · updated
  3. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study sites
    University of Chicago Medical Center · University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center)
    Registry record
    NCT06638307 · updated
  4. A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

    • Phase 1
    • Ages 18 to 55
    • Female participants
    Sponsor
    TerSera Therapeutics LLC
    Study site
    University of Illinois at Chicago
    Registry record
    NCT07310420 · updated
  5. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    University of Illinois Hospital & Health Sciences System
    Registry record
    NCT06827236 · updated
  6. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    ORIC Pharmaceuticals
    Study site
    Northwestern University
    Registry record
    NCT05315700 · updated
  7. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    University of Chicago Hospital
    Registry record
    NCT06465069 · updated
  8. Study of XB010 in Subjects With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    University of Chicago Medical Center
    Registry record
    NCT06545331 · updated
  9. A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Mabwell (Shanghai) Bioscience Co., Ltd.
    Study site
    UChicago Medicine Comprehensive Cancer Center
    Registry record
    NCT06908928 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Chicago, IL on ClinicalTrials.gov.

Lung cancer studies recruiting in Chicago

  1. Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Vivace Therapeutics, Inc
    Study site
    University of Chicago Medical Center
    Registry record
    NCT04665206 · updated
  2. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Chicago Comprehensive Cancer Center
    Registry record
    NCT06287775 · updated
  3. Safety and Feasibility of Intraoperative Visualization With Cytalux in Children

    • Phase 1
    • Ages 6 to 17
    • All sexes
    Sponsor
    Ann & Robert H Lurie Children's Hospital of Chicago
    Study site
    Ann & Robert H. Lurie Children's Hospital
    Registry record
    NCT06235125 · updated
  4. A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BlossomHill Therapeutics
    Study site
    Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion
    Registry record
    NCT06706076 · updated
  5. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Synthekine
    Study site
    University of Chicago
    Registry record
    NCT05098132 · updated
  6. A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Alentis Therapeutics AG
    Study site
    The University of Chicago Medical Center - Oncology
    Registry record
    NCT06747585 · updated
  7. Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Chicago
    Study site
    University of Chicago Medicine Comprehensive Cancer Center
    Registry record
    NCT07782359 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Chicago, IL on ClinicalTrials.gov.

Prostate cancer studies recruiting in Chicago

  1. A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Genentech, Inc.
    Study site
    University of Illinois Hospital & Health Sciences System
    Registry record
    NCT05800665 · updated
  2. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    • Phase 1
    • Ages 18 to 100
    • Male participants
    Sponsor
    Janux Therapeutics
    Study site
    University of Chicago Medical Center
    Registry record
    NCT05519449 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Chicago, IL on ClinicalTrials.gov.

Melanoma studies recruiting in Chicago

  1. A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

    • Phase 1/2
    • From 6 months, up to 17 years
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Call for Information (Investigational Site 0024)
    Registry record
    NCT02332668 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Chicago, IL on ClinicalTrials.gov.

Lymphoma studies recruiting in Chicago

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study sites
    Lurie Children's Hospital-Chicago · University of Chicago Comprehensive Cancer Center · University of Illinois
    Registry record
    NCT04726241 · updated
  2. A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Debiopharm International SA
    Study site
    Northwestern Memorial Hospital
    Registry record
    NCT05765812 · updated
  3. A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    • Phase 1
    • Ages 0 to 18
    • All sexes
    Sponsor
    Autolus Limited
    Study site
    Lurie Children's Hospital
    Registry record
    NCT06173518 · updated
  4. Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT07109219 · updated
  5. Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Chicago Comprehensive Cancer Center
    Registry record
    NCT05272384 · updated
  6. A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    Nuvalent Inc.
    Study site
    University of Chicago Medical Center
    Registry record
    NCT05384626 · updated
  7. A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    The University of Chicago Medical Center (UCMC)
    Registry record
    NCT07101328 · updated
  8. A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

    • Early Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    AIDS Malignancy Consortium
    Study site
    University of Illinois at Chicago
    Registry record
    NCT04139304 · updated
  9. Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Northwestern University
    Registry record
    NCT06015880 · updated
  10. HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Illinois Chicago
    Study site
    University of Illinois at Chicago
    Registry record
    NCT07647432 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Chicago, IL on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Chicago

  1. Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Northwestern University
    Registry record
    NCT05372614 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Chicago, IL on ClinicalTrials.gov.

Ask about studies near Chicago

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call